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Abstract
Background: Developing novel therapeutic agents to treat amyotrophic lateral sclerosis (ALS) has been difficult due
to multifactorial pathophysiologic processes at work. Intrathecal drug administration shows promise due to close
proximity of cerebrospinal fluid (CSF) to affected tissues. Development of effective intrathecal pharmaceuticals will
rely on accurate models of how drugs are dispersed in the CSF. Therefore, a method to quantify these dynamics and a
characterization of differences across disease states is needed.
Methods: Complete intrathecal 3D CSF geometry and CSF flow velocities at six axial locations in the spinal canal
were collected by T2-weighted and phase-contrast MRI, respectively. Scans were completed for eight people with ALS
and ten healthy controls. Manual segmentation of the spinal subarachnoid space was performed and coupled with
an interpolated model of CSF flow within the spinal canal. Geometric and hydrodynamic parameters were then generated at 1 mm slice intervals along the entire spine. Temporal analysis of the waveform spectral content and feature
points was also completed.
Results: Comparison of ALS and control groups revealed a reduction in CSF flow magnitude and increased flow
propagation velocities in the ALS cohort. Other differences in spectral harmonic content and geometric comparisons
may support an overall decrease in intrathecal compliance in the ALS group. Notably, there was a high degree of variability between cases, with one ALS patient displaying nearly zero CSF flow along the entire spinal canal.
Conclusion: While our sample size limits statistical confidence about the differences observed in this study, it was
possible to measure and quantify inter-individual and cohort variability in a non-invasive manner. Our study also
shows the potential for MRI based measurements of CSF geometry and flow to provide information about the hydrodynamic environment of the spinal subarachnoid space. These dynamics may be studied further to understand the
behavior of CSF solute transport in healthy and diseased states.
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Background
Amyotrophic lateral sclerosis (ALS), also known as Lou
Gehrig’s disease, is a devastating neurological disorder of predominately sporadic origin [1] that leads to
severe disability and death. While the majority of cases
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are sporadic, approximately 10% show familial inheritance [2]. ALS results in the loss of upper and lower motor
neurons from the motor cortex, brainstem and spinal
cord. Neurodegeneration in ALS typically advances in a
sequential fashion to the point of phrenic nerve involvement resulting in failure of respiratory effort and death
before degenerative changes are seen elsewhere [3]. ALS
affects approximately 3.9 in 100,000 people within the
United States [4] with approximately equal occurrence
worldwide and does not appear to be linked with environmental toxins. Studies indicate that ALS incidence is
approximately 1.8 times greater in males than females for
unknown reasons [5].
A current challenge in identifying treatments for ALS
is finding reliable measures of efficacy. Historically, survivability is one of the main metrics used in this determination [6]. Through examination of the CSF system we
aim to add to the understanding of ALS pathophysiology
and potentially provide another avenue of diagnosing or
monitoring the disease in a quantitative manner. Developing novel therapeutic agents to treat ALS has also
been difficult because of the high degree of disease heterogeneity and multifactorial pathophysiologic processes
at work [6, 7]. A growing area of research surrounding
ALS treatment is intrathecal (IT) drug administration.
Researchers have investigated safety, tolerability, and
pharmacodynamics of IT injection for a range of ALS
therapeutics [6]. Additionally, filtration of cerebrospinal
fluid (CSF) is actively being developed as a treatment for
cryptococcal meningitis [8], subarachnoid hemorrhage
[9] and has been used experimentally in ALS [10, 11].
To be effective, delivery of IT therapies rely on transport within CSF, movement of the drug across the meninges, transport along the perivascular spaces and finally
absorption into CNS tissue. The use of in vivo measurements along with computer models of CSF solute transport could help maximize drug dispersion and help avoid
toxicity. Magnetic resonance imaging (MRI) is an effective tool for non-invasively measuring CSF flow. Several
studies have already used phase contrast MRI (PCMRI)
to measure and reconstruct CSF flow dynamics in silico
[12–14].
The goal of the present study was to characterize CSF
flow dynamics and geometry in people with ALS compared to healthy controls. A few groups have made strides
towards characterizing CSF dynamics in conditions such
as Chiari malformation [15–21], Syringomyelia [20–22],
and hydrocephalus [23], as well as investigation of CSF
flow dynamics in people with ALS [24]. We expand on
this characterization by providing a more complete analysis of the hydrodynamic environment. Consideration of
hydrodynamics could aid in development of emerging
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therapeutics while also expanding the pathophysiologic
understanding of this disease.

Methods
Inclusion criteria for people with ALS were diagnosis of
clinically suspected or definite ALS and able to tolerate
the MRI scan without contraindications. Exclusion criteria included: presence of connective tissue disorder, previous history of cardiovascular disease, intracranial mass/
deformity, CSF leak, spinal cord tethering, spina bifida,
or myelomeningocele. Ultimately, eight participants with
ALS were recruited from a regional adult population. The
size of this population and restriction on travel compensation further limited recruitment of people with ALS
in this pilot study. Ten healthy adult controls were also
recruited based on the same exclusion criteria and the
inclusion criterion of tolerance for the MRI scan without
contraindications. Prior to each MRI scan, subject height,
weight, waist circumference, heart rate, and blood pressure were recorded. MRI data collection was performed
at Inland Imaging in Spokane, WA.
MRI CSF flow measurement protocol

MRI measurements were obtained on a Siemens 3T
Skyra (Software version syngo MR E11, Siemens Corporation, Munich, Germany). Identical CSF flow measurements were taken for all subjects at six vertebral
locations, Foramen Magnum (FM), C2–C3, C5–C6,
T4–T5, T11–T12, and L3–L4 using PCMRI with retrospective gating from pulse oximetry for 30 cardiac phases
(Fig. 1a). Slice thickness at each location was 5.0 mm with
an in-plane isotropic resolution of 781 µm (~ 150 × 200
pixel FOV). Each slice was oriented perpendicular to the
direction of CSF flow with slice plane aligned at the location of the vertebral disks (Fig. 1d). Values used for the
flip angle, TR, TE, and VENC were 20°, 20.34, 6.69 and
10 cm/s, respectively. Total imaging time to collect all six
slices was ~ 10 min.
CSF flow quantification

The CSF flow rate, QCSF (t), was calculated for each of
the six spinal locations shown in Fig. 1d by importing
the PCMRI data into MATLAB R2016b (The Mathworks Inc., Natick, MA, USA). QCSF (t) was computed
based on the numerical integration of individual pixel
velocities over the CSF
 area ( ACSF ) for an entire carAvoxel [vvoxel (t)], where Avoxel is
diac cycle: QCSF (t) =
the in-plane area of one PCMRI voxel, and vvoxel is the
CSF velocity encoded in that voxel (Fig. 1b). The CSF
waveform for the entire spinal cord (SC) was derived
through interpolation of CSF flow between each of
the six axial measurements. Methods were previously
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Fig. 1 Subject specific example of CSF flow and geometric reconstruction for control 008. a Phase-contrast MRI at each of the six axial locations
along the spine. b CSF flow rate based on PCMRI measurements collected at the FM, C2–C3, C5–C6, T4–T5, T11–T12, and L3–L4. c Axial view of
semi-automatic contrast-based segmentation of T2-weighted MRI slices. d Full spine sagittal T2-weighted MR image including the position of axial
segments of interest. e Final 3D geometric model of the SSS

developed by our group for calculating CSF and cerebral blood flow rates [15, 25] as well as CSF flow interpolation [13, 26].
MRI CSF space geometry protocol

A stack of high-resolution sagittal T2-weighted sampling perfection with application optimized contrasts
using different flip angle evolution (SPACE) magnetic
resonance (MR) images of the complete spinal subarachnoid space (SSS) anatomy was acquired for each
subject (Fig. 1d). These images were acquired with
437 µm isotropic in-plane resolution with 800 µm slice
thickness and spacing in three blocks (craniocervical,
thoracic, and lumbosacral). Total imaging time for both
MRI scan types was ~ 42 min.

CSF space segmentation

The segmentation of MRI data was performed using
the open-source program, ITK-SNAP (Version 3.4.0,
University of Pennsylvania, USA). The MR image set
for each spinal segment was manually reconstructed
from an axial view with the semi-automatic contrastbased segmentation tool (Fig. 1c), as performed by our
group in previous work [17]. Segmentation from the
FM to the end of the dural sac was completed by one of
two trained operators (Figs. 1e and 2). Anatomical fine
structures such as SC nerve roots (except at the filum
terminale) and denticulate ligaments were not possible to accurately visualize, given the MRI resolution
with which the scans were collected. Consequently,
these structures were not included in the segmentation
(Fig. 1e).
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Fig. 2 Geometric models of the spinal subarachnoid space for all subjects created by an expert operator based on T2-weighted MRI data
segmentation. ALS subject 104 is not included as they withdrew from the study before collection of MRI data

Geometric analysis

Similar to our previous studies, computational meshing
was used to calculate the following geometric parameters
along the spine [27]: First, the cross-sectional area of the
SC, Ac , and region bounded by the dura, Ad, were used to
obtain the cross-sectional area of the SSS, Acs = Ad − Ac .
The hydraulic diameter for internal flow within a tube,
DH = 4Acs /Pcs, was calculated based on the cross-sectional area and wetted perimeter, Pcs = Pd + Pc . Wetted
perimeter is the sum of the SC, Pc, and dura, Pd, perimeter. A user-defined function was used to calculate each of
these parameters in ANSYS FLUENT (Ver. 19.2, ANSYS
inc, Canonsburg, PA, USA).
Hydrodynamic analysis

Hydrodynamic environment was assessed at 1-mm slice
intervals along the entire spine by Reynolds number
based on the peak flow rate, and Womersley number
based on hydraulic diameter. In calculating Reynolds
Qsys DH
number, Re = νA
, Qsys is the temporal maximum
cs
of the local flow at each axial location along the spine
obtained by interpolation from the experimental data.
The kinematic viscosity of CSF, given by ν = µ/ρ, was
assumed to be the same as water at body temperature. At
peak systole, the presence of laminar flow along the spine
was characterized using Reynolds number (Re < 2300)

similar to previous studies in CSF mechanics
[13, 17, 26].
√
The Womersley number, α = DH ω/ν , was computed
where ω is the angular velocity of the volumetric flow
waveform with ω = 2/T and ν is the kinematic viscosity
of CSF as defined above. The Womersley number can be
used to characterize the ratio of unsteady inertial forces
to viscous forces for the CSF of the SSS [28]. CSF pulse
wave velocity ( PWV ) along the spine was quantified as
a possible indicator of SSS compliance, as performed in
our previous studies [13, 26]. In brief, a linear fit of the
peak systolic flow arrival time along the spine was used to
compute PWV , equal to the slope of the linear fit.
CSF waveform analysis

For flow rate and frequency analysis, it was necessary to
perform normalization and alignment of the flow data.
CSF flow rate at each of the six axial measurement locations were offset-corrected such that the net flow rate
corresponded to 0 mL/s. Average flow rate was calculated for the C2–C3 location [29]. Because of disparate
temporal offsets introduced by the use of pulse oximetry
in PCMRI phase gating, the steepest decent assessed at
the C2–C3 location was used to align the data in time.
This phase shift was done on a subject-specific basis
with the time shift value calculated at the C2–C3 location applied across all locations. The data was then
extended to 1280 ms during diastole and resampled at
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10-ms intervals to avoid influencing the fast Fourier
transformation (FFT) and to allow temporal comparison
across all subjects. The cardiac cycle over all subjects was
956 ± 138 ms and the longest duration was 1264 ms. For
the frequency analysis, the data at all six axial locations
was spatially normalized by the average flow rate at the
C2–C3 location with the goal to emphasize the flow patterns at all locations rather than to assess the individual
flow rates. The frequency components of the FFT are
expressed in harmonics (−). The data analysis and visualization were performed within MATLAB R2016b.
Statistical analysis

Descriptive statistics were obtained for each parameter
analyzed in terms of mean and standard deviation of values at each axial location for the ALS and control groups.
Average values over the entire spine were also computed
for each parameter along with the total value for parameters such as total spinal cord, dura and SSS volume.
Statistical analysis was conducted in MATLAB R2016b.
Feature points and the individual frequency components were statistically compared with a Mann–Whitney U test. Differences were considered significant at a
p-value < 0.05.

Results
The ALS group was comprised of 7 males and 1 female
with average age of 56 ± 10 years. The control group
included 6 males and 4 females averaging 59 ± 12 years
of age. The tabulated results for all parameters quantified
in the ALS group and corresponding values in the control group may be found in Table 1. MR images of healthy
controls revealed no major abnormalities, such as degenerate disks or CSF stenoses that would be considered
to affect CSF flow dynamics or geometry. One person
with ALS (101) had a nonfunctioning IT pain medication pump and two ALS patients (106 and 108) had a
history of spinal surgery (laminectomy and L4–S1 spinal fusion respectively). These subjects were included in
our final ALS cohort as no anomalies were present in the
SSS geometry. Another person with ALS (102) had near
zero flow at all locations and was therefore excluded from
the flow and hydrodynamic analyses (Figs. 4, 5, 6, 7). In
the case of near zero flow, we confirmed that the PCMRI
sequence triggered correctly by verification of pulsatile
arterial and venous blood flow patterns to the brain visible in the imaging.
Geometric parameters

Visual inspection of the geometries showed a similar
appearance in terms of shape between ALS patients and
controls. One ALS subject (102) had a focal decrease
in SSS cross-sectional area (Fig. 2). Quantitatively,
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Table 1 Geometric and hydrodynamic results
Parameter
Perimeter SC (cm)
Perimeter DM (cm)
Perimeter SSS (cm)
Cross-sectional area SC (cm2)
Cross-sectional area DM (cm2)
Cross-sectional area SSS (cm2)
Volume SC ( Vc) (cm3)
Volume DM ( Vd) (cm3)
Volume SSS ( Vcs) (cm3)
Surface area SC (cm2)
Surface area DM (cm2)
Surface area SSS (cm2)
Hydraulic diameter (cm)
Reynolds number (cm)
Womersley number (α)
Usys (cm/s)
Udia (cm/s)
Qsys (cm3/s)
Qdia (cm3/s)
PWV (cm/s)

Control
Avg.a ± std.
1.87 ± 0.22

5.66 ± 0.78

ALS
Avg.a ± std.
1.88 ± 0.26

5.25 ± 0.83

7.53 ± 0.89

7.13 ± 0.96

2.13 ± 0.54

1.89 ± 0.49

0.35 ± 0.07

1.78 ± 0.53

20.99 ± 2.55

0.35 ± 0.08

1.53 ± 0.48

22.53 ± 2.29

129.19 ± 18.67

119.83 ± 21.74

113.52 ± 7.67

119.37 ± 6.59

108.20 ± 18.67

344.12 ± 27.30

97.30 ± 20.51

333.54 ± 39.72

457.64 ± 29.89

452.91 ± 43.82

194.74 ± 80.75

209.37 ± 37.34

− 1.30 ± 0.34

− 1.29 ± 0.33

− 1.88 ± 0.62

− 1.58 ± 0.31

347.41 ± 88.13

473.19 ± 162.04

0.96 ± 0.21

12.71 ± 1.48

0.76 ± 0.30

1.06 ± 0.29

0.89 ± 0.21

11.92 ± 1.51

0.70 ± 0.28

0.83 ± 0.17

DM dura matter, PWV pulse wave velocity, SC spinal cord, SSS spinal
subarachnoid space, Qdia average diastolic CSF flowrate, Qsys average systolic CSF
flowrate, Usys average systolic CSF velocity, Udia average diastolic CSF velocity
a

Average values are based 1 mm slice intervals along the entire spine

cross-sectional area of the dura was found to be 11%
smaller in the ALS group with the greatest difference tending to be within the dural sac region (Fig. 3a).
Note, parameters are plotted with respect to their normalized axial distance below the foramen magnum.
Axial SC area was nearly identical for the two groups
(0.35 cm2, Fig. 3b and Table 1). The ALS group had a 14%
smaller cross-sectional SSS area than the healthy controls
(1.53 cm2 and 1.78 cm2 respectively, Fig. 3c and Table 1).
Similarly, the perimeter of the dura and SSS also tended
to be slightly smaller in the ALS group compared to
healthy controls within the dural sac region (Fig. 3d, f ).
No difference was observed in the perimeter of the SC
(Fig. 3e). Average volume (Table 1) of the SSS in the ALS
group (97.3 cm3) was 10% less than the control group
(108.2 cm3).
CSF flow characteristics

All flow rates from the PCMRI data measured at the FM,
C2–C3, C5–C6, T4–T5, T11–T12, and L3–L4 vertebral
locations are plotted for both the control (blue) and ALS
(red) groups, excluding ALS case 102 in Fig. 4. Compared
to the control group, peak systolic CSF flow in the ALS
group was larger at C2–C3, comparable at FM, C5–C6,
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Fig. 3 Average geometric parameter values for the ALS group (red) plotted with those of the control group (blue) in relation to distance from the
FM in terms of: a cross-sectional area of dura, b cross-sectional area of spinal cord, c cross-sectional area of the subarachnoid space, d perimeter of
dura, e perimeter of spinal cord, f perimeter of subarachnoid space. Parameters are plotted with respect to their normalized axial distance below
the forament magnum

T4–T5 and T11–T12, and smaller at L3–L4. Only the
feature point of the FM peak systolic CSF flow was significantly faster between the two groups (p = 0.0136). The
maximum peak systolic CSF flow feature points assessed
for every subject individually, again excluding ALS case
102 as noted above, are marked at their mean with the
corresponding standard deviation error bars regarding
timing and flow in Fig. 4.

Average CSF PWV along the spine was 36% faster in
the ALS group (473 cm/s) compared to the control group
(347 cm/s) (Table 1). The average spatial–temporal distribution of the CSF PWV for all ALS subjects excluding 102, and controls is shown in Fig. 5. Peak systolic
CSF flow magnitude occurred at a normalized distance
of ~ 0.05 below the FM in patients and ~ 0.2 in controls
(Fig. 5).
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Fig. 4 Flow rates of all subjects at the six axial locations along the spine for the ALS (red) and the control (blue) groups. The respective mean
flow rate over the ALS and the control group are depicted in the bold lines. The feature points are marked at the peak systolic CSF flow with the
corresponding standard deviation error bars regarding timing and flow. The FM’s peak systolic CSF flow is significantly different between the two
groups regarding timing (p = 0.0136) as evaluated by the Mann–Whitney U test. Note that the y-axis scale for T11–T12 and L3–L4 are different from
the other four axial locations

Spectral analysis revealed that the frequency components of the normalized flow rate for the ALS (red) and
the control (blue) groups are significantly different (*)
for the first, second, sixth and seventh harmonic of the
T11–T12 location (p = 0.0031, p = 0.0136, p = 0.0097,
and p = 0.0330), and for the sixth harmonic of the L3–L4
location (p = 0.0330). The frequency components are presented from the first to the seventh harmonic in Fig. 6.
Hydrodynamic parameters

All hydrodynamic parameters of interest for both the
ALS group, excluding subject 102, and the control
group are shown in Fig. 7 and Table 1. The systolic and
diastolic CSF flow velocity along the length of the spinal
cord tended to be smaller for the ALS group compared
to the control group except for immediately inferior
to the FM and near the dural sac (Fig. 7a). Considering both CSF geometry and velocity, the average peak
systolic flow in the ALS group was 16% less than that

of the control group. The average peak diastolic flow
in the ALS group was 21% less than the control group
(Fig. 7b). Reynolds number for the control group was
194.74 and 209.35 in the ALS group indicating laminar
flow in both groups. Reynolds number was greater for
the ALS group at a normalized distance of ~ 0.1 below
the FM and again at ~ 0.9 (Fig. 7c). On average, HD in
the ALS group was 7% smaller at .89 cm vs .96 cm in
the control group. Womersley number behaved in a
similar manner between groups for the length of the SC
(Fig. 7d, right y-axis label).

Discussion
The present study quantified geometric parameters
in the spinal canal of eight people with ALS and ten
healthy controls. CSF hydrodynamics were also possible
to quantify and compare in seven people with ALS and
ten healthy controls. This section includes the findings
we feel warrant further investigation as they may have an
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Fig. 5 Spatial–temporal distribution of the interpolated CSF flow rates along the length of the spinal canal in the healthy control and ALS groups

Fig. 6 Frequency components of the normalized flow rate at the six axial locations along the spine for the ALS (red) and the healthy control (blue)
groups. In each panel, the harmonics are divided by the dotted line and are presented from the first to the seventh harmonic. Significant harmonics
are marked with asterisk at the respective harmonics as analyzed with the Mann–Whitney U test. The first, second, sixth, and seventh harmonic of
T11–T12 are significantly different (p = 0.0031, p = 0.0136, p = 0.0097, and p = 0.0330), and at L3–L4 for the sixth harmonic (p = 0.0330)
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Fig. 7 Average values for the hydrodynamic parameters quantified for ALS (red) and healthy controls (blue) along the spine in terms of: a peak
mean velocity, b peak flow rate, c Reynolds number and d hydraulic diameter (left y-axis) and Womersley number (right y-axis)

impact on drug delivery strategies and the monitoring of
ALS progression.
Key CSF dynamics findings

Timing of peak systolic CSF velocity at the FM was significantly faster for the ALS group (p = 0.0136). Notably, one control subject had slower peak systolic CSF
flow. However, because the flow amplitude was within
the normal range, this subject was not considered an
outlier as with ALS subject 102. Despite inclusion of
this subject in the statistical analysis, timing at the
FM was still found to be significantly faster in the ALS
cohort. Overall, average CSF pulse wave velocity along
the spine was elevated in the ALS group (473.19 cm/s)

compared to the control group (347.41 cm/s) (Table 1).
The average spatial–temporal distribution of the CSF
PWV for all patients and controls is shown in Fig. 5.
Elevated PWV may indicate an overall decrease in SSS
compliance; however, arrival time of peak CSF flow
was only significantly faster for the ALS group near the
FM as evidence by analysis of peak CSF flow timing
(Fig. 4). Peak systolic CSF flow magnitude occurred at
a normalized distance of ~ 0.05 below the FM in people with ALS and ~ 0.2 in controls (Fig. 7b). CSF flow
amplitude in the ALS group was only greater at the
C2–C3 location and smaller at C5–C6, T11–T12, and
L3–L4 than in the control group. These differences
may be further indication of an overall decrease in
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SSS compliance with emphasis on the thoracolumbar
region where changes in the spectral content of the
normalized flow waveforms was most significant in the
ALS group.
Reliability of MRI based measurements of CSF
hydrodynamics

Due to the sensitivity of hydrodynamic parameters
to both geometry and CSF flow, it is important that
the measurement technique is robust enough to produce reliable results. In a previous study by our group,
Khani et al. 2019, quantified scan-rescan reliability for
geometric and hydrodynamic parameters in cynomolgus monkey for which geometric parameters displayed
good follow-up agreement [12]. Hydrodynamic agreement was also found to be positive although to a lesser
correlative degree due to expected CSF flow variability
at the 2-week follow-up scan. In cynomolgus monkeys,
174 and 123 voxels were used to quantify the average
axial SSS cross-section for geometric and CSF flow
analysis respectively. For the present study, 551 and
250 voxels were used to quantify the average axial SSS
cross-section in human controls for geometric and
CSF flow analysis respectively. In addition, the lower
CSF flowrates observed in cynomolgus monkey are
more difficult to measure than those found in humans.
Thus, while scan-rescan reliability was not quantified in the current study, lower relative precision in
cynomolgus likely result in a lower bounds of scan
repeatability for identical techniques in humans. CSF
PWV quantification has also been applied previously
in healthy controls [30]. However, the exact test–retest
reliability has not yet been quantified.
Inter-operator reliability of MRI based hydrodynamics has also been studied by our group [17].
T2-weighted MRI data collected using a 1.5 T magnet and 1.0 mm isotropic scan resolution of a healthy
subject was analyzed by four operators using identical
methods as the present study. The maximum coefficient of variation (CV) for cross-sectional area, peak
systolic CSF flow, and Reynolds number were found
to be 12.2%, 16.8% and 12.6% respectively. In the current study, CV for cross-sectional area, peak systolic
CSF flow, and Reynolds number were 29.8%, 26.2%
and 41.5% respectively for healthy controls and 31.4%,
25.6% and 17.8% in the ALS group. This suggests interindividual variability in and across groups is above the
level explained by inter-operator variability alone.
Additionally, in vitro studies have been performed
by our group to quantify the reliability of MRI for
CSF geometric and flow measurements. Yildiz et al.
2017, found a CV of 4.8% for peak CSF flow at a single location [31] and Thyagaraj et al. 2017, found a
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an average CV of 8% for peak CSF flow across several
locations [32]. Geometric reconstruction was also analyzed by Thyagaraj et al. 2017, and found to be in good
agreement with the digital. STL geometry used to create the flow phantom; however, some systematic over
estimation in reconstructed geometric variables was
noted [32]. Overall, these observations provide further
support for the robustness of the current method to be
sufficient for observation of differences in and among
groups.
Comparison of geometric results to previous studies

Review of CSF volume within the SSS was provided by
Sass et al. 2017, and averaged 80.0 cm3 for all studies
reporting values of the complete SSS [26]. In our study,
CSF volume in the SSS averaged 97.3 cm3 for the ALS
group, 10% less than the control group at 108.2 cm3.
Qualitatively, this difference was not evident based on
visual inspection, which revealed a similar degree of geometric variability between both ALS and control cohorts
(Fig. 2). Volumetric calculations are sensitive to small
changes in segmentation accuracy which is itself dependent on image resolution. While somewhat higher, our values for SSS volume are well within the range of reported
values. Furthermore, when compared against average
SSS volume from the small number of manual segmentations of healthy subjects, agreement is notable with those
studies also averaging 108.2 cm3. Finally, trends in axial
distribution of cross-sectional areas within our study for
both spinal cord and dura show good similarity to Loth
et al. 2001 [28], with peaks in SSS area located at the FM
and lumbar enlargement (Fig. 3a, b). While T2-weighted
MRI data for the full cranial volume was captured as part
of the scanning protocol, we did not capture CSF flow
around the brain or aqueduct of Sylvius. This was due to
consideration of patient time in the scanner approaching 1 h, and especially the sensitivity of the ALS group to
prolonged supine position.
MRI based ALS biomarkers investigated in previous studies

The ideal ALS biomarker would have sufficient sensitivity and specificity for the syndrome, predict regional
involvement and symptom spread, ability to differentiate clinical phenotypes, and be based on easily accessible
and affordable technology [33]. CSF-based biomarkers
such as CSF hydrodynamics show promise because of the
CSF’s innate proximity to the location of disease involvement. Recent studies have shown that there is rapid
exchange of CSF with the brain parenchyma during sleep
acting to wash the brain [34, 35] as well as a possible
glymphatic mechanism which removes waste products
from the CSF [36]. Therefore, disruption of normal CSF
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dynamics could, in principle, play a role in the progression of degenerative CNS disease.
While many MR imaging techniques have been used
to investigate ALS biomarkers and disease progression
[33, 37], the primary focus has been the CNS tissue,
rather than the CSF surrounding that tissue. Conversely,
research evaluating ALS molecular biomarkers in the
CSF has been well established for many decades with a
large number of possible disease biomarkers identified
often in elevated levels. Disruption of the BBB has been
implicated in a number of neurodegenerative diseases
and is also possible to study through MRI imaging [38,
39]. Coupling this understanding with CSF distribution and flow dynamics may provide further insight and
predictors into the rate or mechanisms of the disease
progression.
Progressive death of motor neurons in ALS leads
to observable changes in the brain and spinal cord as
highlighted by El Mendili et al. 2019 [40]. Longitudinal
studies have established a connection between cervical spinal cord atrophy and functional decline in ALS
patients [41–43]. Additionally, reviews on the utility of
various imaging techniques for visualizing changes in
CNS have discussed a potential use in the diagnosis and
tracking of ALS [33, 44, 45]. In particular, a study Sato
et al. 2012 [24], utilized PCMRI to evaluate CSF pulsatility in 40 subjects with motor neuron disease as well as 14
healthy controls. An average peak systolic CSF velocity
of − 6.0 cm/s, − 5.4 cm/s and − 3.3 cm/s for was found
for combined motor neuron disease, elderly controls and
young controls, respectively. Furthermore, no significant
difference of CSF pulse wave timing at C5 was found
between the study groups. Flow velocities reported in
the above study are somewhat higher than those found
by our group (Fig. 7a). However, it should be noted that
these measurements were taken at two small regions of
interest bilaterally adjacent to the spinal cord. Our group
has previously shown that CSF flow distribution is variable across the spinal canal cross-section and can include
localized flow “jets” [13]. We therefore considered the
average CSF velocity across the entire SSS cross-section
which includes regions of both high and low flow rates.
Finally, regarding CSF pulse wave timing, the aforementioned study by Sato and colleagues is consistent with our
findings at the analogous location of C5/C6 finding no
statistical difference. Importantly, our study contributes
a novel analysis of hydrodynamics across the entire SSS
geometry based on CSF flow measurements across the
full SSS cross-section at multiple locations.
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Potential implications for intrathecal ALS therapeutics

The proximity of CSF with the CNS tissue makes it a
potential route for ALS treatment using intrathecal drug
delivery. While IT drug delivery is a growing field, due to
a gap in foundational knowledge and higher associated
risks, IT devices and therapeutics are not common clinically [46]. Intrathecal delivery baclofen is among the only
IT therapy regularly prescribed for ALS where systemic
side-effects are dose limiting and pain due to severe
spasticity cannot be effectively managed by other means
[47–49]. Ultimately, intrathecal baclofen is not a disease
modifying treatment and symptomatic benefits need to
be carefully titrated against retention of beneficial muscle
tone [50].
At present, only two approved therapies, Riluzole and
Edaravone, are shown to potentially produce modest
delay in ALS progression, however neither is administered intrathecally in humans [51]. Intrathecal delivery
of Riluzole has been investigated in both Gottingen minipigs and canine models [52, 53] with both studies demonstrating higher Riluzole levels in the CNS while limiting
the systemic dose that may lead to off-target side-effects.
Additionally, gene therapy and therapies involving
trophic factors to stimulate dying neurons [54, 55] have
shown promise in rodent models. Other animal studies have also shown that human stem cells administered
intrathecally delay the onset of symptoms and prolong
survival in ALS transgenic mice [56]. The mechanism by
which preservation, and in some cases, regeneration of
motor neurons occurs appears to be due to production
of growth factors and other neuroprotective compounds
that can be found in CSF [56, 57]. Additionally, alteration of the neurotoxic environment observed in ALS
is another potential target for treating this devastating
disease [58–60] and could be effected via CSF filtration
[10, 11]. This could potentially improve the survivability
of transplanted stem cells and improve effectiveness of
other IT treatments. Overall, most potential IT therapeutic approaches for ALS remain experimental and are
often based on specific induced forms of the disease in
animal models. While the reduction of the above findings
to clinical application is yet to be seen, the potential for
CSF hydrodynamics to inform the design and application
of new IT therapeutics and devices is still clear.
The observed differences in systolic and diastolic flow,
volume of the SSS, and CSF geometric and hydrodynamic properties are important for development of accurate models for IT drug administration and manipulation
of the spinal CSF environment. Several studies have used
MRI data (frequently of healthy individuals) to derive
in vitro and computer-generated models for analyzing
dispersion of compounds in the SSS and pulsatile flow is
consistently indicated as one of the major contributors to
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CSF mixing [12, 61–64]. One of our subjects (102) exhibited nearly zero CSF flow while others had more modest
decreases compared to controls. This subject also had a
local SSS restriction in the cervical spine that was present around the entire circumference of the spinal cord as
well as suspected redundant nerve root syndrome in the
lumbar spine (Fig. 2). While local variability in the crosssectional area of the SSS was noticeable in both groups,
with the exception of ALS subject 102, there were no visible features which could consistently be correlated with
CSF dynamics (Fig. 2). In the case of ALS subject 102, it
is likely that the observed restrictions decreased the CSF
pulsation along the entire spine. Because the rate of diffusion within spinal CSF is many orders of magnitude
slower than in advective mixing, this type of focal restriction could have an important impact in context of IT solute transport [65].

Limitations

Several limitations exist in our study. Findings for both
groups were based on a relatively small sample. Rarity and variability of the disease combined with careful screening against the ability to undergo a protracted
MRI-scan presented a distinct challenge in finding participants on a regional level. Secondly, our control group
was not ideally matched against our ALS group and both
groups included subjects with confounding conditions.
While these factors negatively impacted the statistical
power of the results in this study, it is straightforward to
expand this data set in future with additional subjects.
Furthermore, a longitudinal study would also allow comparison of any observations with disease progression.
Lastly, while raw data was collected at a relatively high
resolution, micro anatomy such as nerve roots, and denticulate ligaments were not possible to visualize. While
important for specific transport dynamics, nerve roots
did not have a large effect on unsteady CSF velocities as
show in our previous computational study [27]. Similarly,
flow measurements were made at only a few locations
along the spinal canal and it was not possible to capture
transient flow phenomena due to phase averaging. This
was primarily a practical limitation of scan duration
which was already at ~ 45 min.

Conclusion
This study characterized CSF flow dynamics alongside geometric parameters in humans with ALS as
well healthy controls. We found significant differences
in peak systolic CSF flow timing at the FM, as well
significant differences in the spectral content of CSF
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waveforms between ALS and control cohorts. More
modest and non-significant differences in the CSF
dynamics of our ALS group showed reduced CSF flow
magnitude and increased PWV. While our study lacks
sufficient power to draw definite conclusions regarding
the differences we observed, we believe they deserve
further investigation because of their potential importance related to intrathecal solute transport. In particular, a growing interest in IT drug delivery and the
possible connection of trophic and neurotoxic factors
in the CSF with disease progression warrant further
study of CSF dynamics in the disease state. With the
high degree of heterogeneity that exists among ALS
cases it may be beneficial to conduct larger, longitudinal studies to determine how changes in CSF flow correlate with disease progression. This may contribute
to the understanding of the pathologic progression of
ALS, particularly if the onset of a neurotoxic CSF environment and breakdown of CSF flow were to coincide.
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